白内障术后玻璃体内地塞米松植入剂对糖尿病性黄斑水肿的影响
这项前瞻性单臂开放标签研究纳入24例2型糖尿病合并至少轻度糖尿病视网膜病变患者,在白内障超声乳化及人工晶状体植入术后立即植入地塞米松玻璃体内植入剂(DEX;Ozurdex 700 μg;Allergan)。术后3个月内黄斑中心凹视网膜厚度(CRT)较基线无显著变化,最佳矫正视力显著改善,未出现眼压≥22 mmHg或严重不良事件。作者认为短期结果提示术中单次DEX注射可能避免糖尿病患者白内障术后CRT增加。
要点
- 术后1周、1个月、3个月CRT较基线均无显著变化,无眼出现CRT术后增加>50 μm。
- 最佳矫正视力从基线0.37(20/50)显著改善至术后1个月和3个月0.12(20/25)(P < 0.001)。
- 随访期间无患者眼压≥22 mmHg,无严重不良事件。
核心结论
- 这些短期结果提示,超声乳化术后术中单次DEX注射可能避免糖尿病患者白内障术后CRT增加。
研究设计与样本
- 前瞻性、单臂、开放标签研究(ClinicalTrials.gov注册号NCT01748487),纳入24例2型糖尿病合并至少轻度糖尿病视网膜病变并接受白内障手术及超声乳化后DEX植入联合人工晶状体植入的患者。
主要发现
- 平均CRT从基线241.1 μm(95%CI 227.5-254.6 μm)变为术后1周236.9 μm(95%CI 223.9-249.9 μm,P = 0.09)、1个月238.9 μm(95%CI 225.5-252.3 μm,P = 0.44)、3个月248 μm(95%CI 232.4-260.8 μm,P = 0.15)。
- 任何随访时点均无眼出现CRT术后增加>50 μm;8.3%的眼出现CRT增加10%。
- 平均最佳矫正视力从基线0.37(20/50)显著改善至术后1周0.19(20/30)、1个月0.12(20/25)、3个月0.12(20/25)(每次比较P < 0.001)。
- 术前平均眼压为13.8 mmHg,任何随访时点均无患者出现眼压≥22 mmHg,随访期间无患者发生严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 μm (95% confidence interval, 227.5-254.6 μm) at baseline to 236.9 μm (95% confidence interval, 223.9-249.9 μm) at 1 week (P = 0.09), 238.9 μm (95% confidence interval, 225.5-252.3 μm) at 1 month (P = 0.44), and 248 μm (95% confidence interval, 232.4-260.8 μm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 μm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients.
引用
- Calvo P, Ferreras A, Al Adel F, et al. EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY. Retina. 2018. PMID: 28196056. doi:10.1097/IAE.0000000000001552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。